Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Temozolomide 45Radiotherapy 17Magnetic Resonance Spectroscopy 17Specimen Handling 14Bevacizumab 12pembrolizumab 11Lomustine 9Radiation 8fludarabine 7Cyclophosphamide 7atezolizumab 4Biopsy 4olaparib 3Transurethral Resection of Bladder 3Surgical Procedures, Operative 3Nivolumab 3Leukapheresis 3D2C7-(scdsFv)-PE38KDEL 3Blood Specimen Collection 3Aminolevulinic Acid 3regorafenib 2fluciclovine F-18 2contrast agent BR1 2antisecretory factor 2abemaciclib 2Restraint, Physical 2Re-Irradiation 2Radiation Dose Hypofractionation 2Palliative Care 2Oncolytic Virotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Glioblastoma × azeliragon × Clear all
NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡